Leonard Frank X's Form 4 filing
NovoCure Ltd (NVCR) · filed Feb 29, 2024
- Accession no.
- 0001562180-24-001988
- Filed
- Feb 29, 2024
- Trade date
- Feb 27-28, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $33.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Frank XCIK 0001822879 | Officer (EVP, Pres., Novocure Oncology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Ordinary Shares | AGrant or awardAcquired | +102,249 | $16.30 | +$1,666,658.7 | 164,695 | Direct | |
| Feb 28, 2024 | Ordinary Shares | SSaleDisposed | −2,078 | $16.14 | −$33,538.92 | 162,617 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Ordinary Shares | AGrant or awardAcquired | +156,348 | $16.30 | +$2,548,472.4 | 156,348 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.